Forbes December 8, 2024
John Werner

In some of the most interesting use cases for artificial intelligence, the digital processes are applied to a physical supply chain.

At MIT’s Engine, an incubator and co-working space with many teams working on various inventions, Ashley Beckwith does research for a startup called Foray Bioscience, with the goal of disrupting conventional manufacturing of wood products, and pursuing targeted reforestation.

Estimating that the world has lost a half million acres of forest in the last quarter of a century, Foray is looking at the possibility of getting live cells from plants to develop synthetic products.

Beckwith is pursuing cell culture and tissue engineering: in a recent Planet Action presentation, she talked about how to envision and then tackle the problem.

...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, Pharma / Biotech
Zealand Pharma, Roche Reach Potential $5.3 Billion Deal to Develop Petrelintide for Weight Management
STAT+: Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche Puts Up $1.65B to Partner With Zealand on ‘Future Foundational Therapy’ for Obesity
Ono pays $280M to license Ionis rare disease drug

Share This Article